Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
aTYR PHARMA INC (LIFE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the third quarter of 2023. Ended the second quarter of 2023 with $112.0 million in cash, cash equivalents and investments. SAN DIEGO – August 9, 2023 – aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2023 results and provided a corporate update. “Throughout the second quarter we have continued to progress and invest in our clinical development program for our lead therapeu..."
05/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATIONOF",
"ATYR PHARMA, INC. 2015 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan . The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of aTyr Pharma, Inc., a Delaware corporation , and its Subsidiaries upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and stre...",
"Code of Business Conduct and Ethics Introduction Purpose and Scope The Board of Directors of aTyr Pharma, Inc. established this Code of Business Conduct and Ethics to aid the Company’s directors, officers and employees in making ethical and legal decisions when conducting the Company’s business and performing their day-to-day duties. The Company’s Board of Directors or a committee of the Board is responsible for administering the Code. The Board has delegated day-to-day responsibility for administering and interpreting the Code to a Compliance Officer. Our General Counsel has been appointed the Company’s Compliance Officer under this Code. The Company expects its directors, officers and employees to exercise reasonable judgment when conducting the Company’s business. The Company encourages..."
05/09/2023 8-K Quarterly results
Docs: "aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to initiate in the third quarter of 2023. Company to host multiple presentations for efzofitimod at the upcoming American Thoracic Society 2023 International Conference. February follow-on common stock offering generated $48.1 million in net proceeds. Ended the first quarter 2023 with $117.6 million in cash, cash equivalents and investments. SAN DIEGO – May 9, 2023 – aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA s..."
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/09/2023 8-K Quarterly results
Docs: "aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to begin in 2023. February 2023 follow-on common stock offering of approximately $52.0 million in gross proceeds. Company to host conference call and webcast today, March 9th, at 5:00 p.m. EST / 2:00 p.m. PST. SAN DIEGO – March 9, 2023 – aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update. “2022 was..."
02/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "22,225,000 Shares ATYR PHARMA, INC. Common Stock UNDERWRITING AGREEMENT February 8, 2023 RBC CAPITAL MARKETS, LLC As Representative of the several Underwriters named in Schedule I hereto c/o RBC Capital Markets, LLC Brookfield Place 200 Vesey Street, 8th Floor New York, New York 10281",
"3545 John Hopkins Court, Suite"
02/06/2023 8-K Other Events  Interactive Data
11/10/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
04/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Certificate of Amendment to Restated Certificate of Incorporation of aTyr Pharma, Inc",
"ATYR PHARMA, INC. 2015 STOCK OPTION AND INCENTIVE PLAN",
"ATYR PHARMA, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN"
04/22/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "OPEN MARKET SALE AGREEMENT SM",
"3545 John Hopkins Court, Suite"
04/14/2022 8-K/A Other Events  Interactive Data
04/13/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
03/14/2022 8-K Quarterly results
Docs: "Cash & Investment Position: Cash, cash equivalents and investments as of December 31, 2021, were $107.9 million. 2 • R&D Expenses: Research and development expenses were $23.3 million for the year ended 2021, which consisted primarily of product development costs for the efzofitimod and ATYR2810 programs. Program costs for efzofitimod included preparation for the upcoming planned registrational trial in pulmonary sarcoidosis, which included the manufacture of clinical trial material and initiation of technology transfer activities with FUJIFILM Diosynth Biotechnologies. Program costs for ATYR2810 included costs related to IND-enabling activities and the initiation of manufacturing activities with Lonza. ● G&A Expenses: General and administrative expenses were $10.8 million for the ye..."
11/10/2021 8-K Quarterly results
Docs: "Cash & Investment Position: Cash, cash equivalents and investments as of September 30, 2021 were $116.4 million. ● R&D Expenses: Research and development expenses were $5.1 million for the third quarter of 2021, which consisted primarily of product development costs for ATYR1923 and ATYR2810 programs. ● G&A Expenses: General and administrative expenses were $2.6 million for the third quarter of 2021. ● Shares Outstanding: Commons shares outstanding were 27,790,677 as of September 30, 2021. 3 Conference Call and Webcast Details aTyr will host a conference call and webcast today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to discuss its financial results and provide a corporate update. Interested parties may access the call by dialing toll-free 844-358-9116 from the ..."
09/16/2021 8-K Quarterly results
09/13/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
Docs: "Cash & Investment Position: Cash, cash equivalents and investments as of June 30, 2021 were $44.1 million. ● R&D Expenses: Research and Development expenses were $7.7 million for the second quarter of 2021, which consisted primarily of ATYR1923 and ATYR2810 program costs. ● G&A Expenses: General and administrative expenses were $2.8 million for the second quarter of 2021. ● Shares Outstanding: Commons shares outstanding were 16,919,872 as of August 9, 2021. Conference Call and Webcast Details aTyr will host a conference call and webcast today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to discuss its financial results and provide a corporate update. Interested parties may access the call by dialing toll-free 844-358-9116 from the US, or 209-905-5951 internationally..."
05/25/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
02/09/2021 8-K Quarterly results
01/25/2021 8-K Investor presentation
Docs: "aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression Poster highlights NRP2 expression on immune cells in the tumor microenvironment.",
"Poster Presentation titled “Neuropilin-2 is Expressed on Immune Cells Present in the Tumor Microenvironment, and May Contribute to the Suppression of Immune Regulation Leading to Progression and Metastasis of Cancer.”"
01/22/2021 8-K Investor presentation
Docs: "aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition.",
"Poster Presentation titled “A Mass Spectrometry Proteomics-Based Approach to Identify Target Receptors for Novel Extracellular tRNA Synthetase Fragments.”"
01/14/2021 8-K Quarterly results
01/08/2021 8-K Investor presentation
Docs: "Corporate Presentation Materials of aTyr Pharma, Inc. dated January 2021"
01/04/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Third Quarter 2020 Financial Results"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy